Physician profile
Judith E Rosso
NPI 1346246949
$837.05
in general payments reported to CMS, 2019-2025
20 companies · $298 in 2025
The $298 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $21.24 · 2020: $55.07 · 2021: $57.44 · 2022: $168 · 2023: $136 · 2024: $101 · 2025: $298.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $535.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $535.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $144.24 | 2021-2025 | |
| Glaxosmithkline, LLC. | $101.53 | 2022-2024 | Shingrix, Arexvy |
| Merck Sharp & Dohme LLC | $94.97 | 2022-2023 | Belsomra |
| Otsuka America Pharmaceutical, INC. | $63.59 | 2022-2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $54.29 | 2025 | |
| Idorsia Pharmaceuticals US INC | $51.82 | 2022-2023 | Quviviq |
| Pfizer INC. | $39.80 | 2025 | |
| Tactile Systems Technology INC | $33.83 | 2021-2025 | Flexitouch Plus, Nimbl |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $33.56 | 2025 | Caplyta |
| Tanabe Pharma America, INC. | $30.09 | 2023 | |
| Amgen INC. | $29.64 | 2024-2025 | Otezla, Repatha, Repatha |
| Acadia Pharmaceuticals INC | $23.61 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.24 | 2019 | |
| Eisai INC. | $20.09 | 2020 | |
| Astellas Pharma US INC | $18.73 | 2025 | Veozah |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $17.64 | 2024 | Eterna |
| Biohaven Pharmaceutical Holding Company Ltd. | $16.91 | 2022 | |
| Lilly USA, LLC | $15.55 | 2025 | Zepbound, Mounjaro |
| Hologic Sales and Service, LLC | $14.55 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $11.37 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Judith Rosso listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.